Optimization of the control of blood pressure. What contribution can be obtained from use of combinations of fixed doses of ACE inhibitors and calcium channel blockers?


Cite item

Full Text

Abstract

Basing on the results of large trials investigating efficacy of combined use of angiotensin-converting enzyme inhibitors (as a rule, perindopril) and calcium channel blockers (as a rule, amlodipin), the article analyses variety of mechanisms of their combined action, effects on dynamics of blood pressure, heart rate variability. The above combined treatment significantly reduces frequency of cardiovascular complications, improves the course of diabetes mellitus in its combination with arterial hypertension, renal function in patients with chronic renal failure and arterial hypertension. It is important to use fixed doses of the above drugs.

About the authors

Oleg Maksimovich Eliseev

Email: dubrovo@list.ru

O M Eliseev

Cardiological Research Center, Moscow

Cardiological Research Center, Moscow

References

  1. Kearney P. M., Whelton M., Reynolds K. et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223.
  2. Ezzati M., Lopez A. D., Rodgers A. et al. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360(9343): 1347-1360.
  3. Blood Pressur Lovering Treatment Trialists Collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003; 362: 1527-1535.
  4. Мясников А. Л. Гипертоническая болезнь. М.: Медгиз; 1954. 310-341.
  5. Wolf-Maier K., Cooper R. S., Kramer H. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10-17.
  6. Cutler J. A., Sorlie P. D., Wolz M. et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008; 52: 818-827.
  7. Метелица В. И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. 3-е изд. М.: МИА; 2005.
  8. Chobanian A. V. The hypertension paradox - more uncontrolled disease despite improved therapy. N. Engl. J. Med. 2009; 361: 878-887.
  9. Collins R., Peto R. Antihypertensive drug therapy: effects on stroke and coronary heart disease. In: Swales J. D., ed. Textbook of hypertension. Oxford: Blackwell Scientific publications; 1994. 1156-1164.
  10. Sever P. S., Dahlóf B., Poulter N. R. et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J. Hypertens. 2001; 19: 1139-1147.
  11. Dahlóf B., Sever P. S., Poulter N. R. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
  12. Chobanian A. V., Bakris G. L., Black H. R. et al. The Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
  13. European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. Guidelines Committee. J. Hypertens. 2003; 21: 1011- 1053.
  14. ESH - ESC. 2007 Guidelines for the management of arterial hypertension. J. Hypertens. 2007; 25: 1105-1187.
  15. Mancia G., Laurent S., Agabiti-Rosei E. et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. 2009; 27(11): 2121-2158.
  16. Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского общества кардиологов. Диагностика и лечение артериальной гипертонии. Кардиоваск. тер. и профилакт. 2008; 6 (прил. 2).
  17. Gerbino P. P., Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am. J. Hlth Syst. Pharm. 2007; 64(12): 1279- 1283.
  18. Jamerson K., Weber M. A., Bakris G. L. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
  19. Fox K. M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double blind, placebo controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
  20. Ferrari R. Angiotensin converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Exp. Rev. Cardiovasc. Ther. 2005; 3: 15-29.
  21. Weir M. R. Calcium channel blockers: their pharmacologic and therapeutic role in hypertension. Am. J. Cardiovasc. Drugs 2007; 7(Suppl. 1): 5-15.
  22. Poulter N. R., Wedel H., Dahlof B. et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-913.
  23. Rothwell P. M., Howard S. C., Dolan E. et al. Effects of β-blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010; 9(5): 469-480.
  24. Rothwell P. M., Howard S. C., Dolan E. et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895- 905.
  25. Ferrari R. Angiotensin converting enzyme inhibitor-calcium antagonist combination: an alliance for cardioprotection? J. Hypertens. 1997; 15(Suppl.): S109-117.
  26. Ferrari R., Visioli O. Protective effects of calcium antagonists against ischemia and reperfusion damage. Drugs 1991; 42(Suppl. 1): 14-26.
  27. Ferrari R. Mechanisms of protective effects of angiotensin-conwerting enzyme inhibitors in myocardial ischemia. In: Fox K., Remme W. ACE inhibition and ischemic heart disease. London; Science Press; 1999. 13-23.
  28. Pepine C. J., Handberg E. M., Cooper-DeHoff R. M. et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. J. A. M. A. 2003; 290: 2805-2816.
  29. Bahl V. K., Jadhav U. M., Thacker H. P. Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG prospective, observational, multicenter study. Am. J. Cardiovasc. Drugs 2009; 9(3): 135-142.
  30. Fogari R., Malamani G. D., Zoppi A. et al. Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J. Hum. Hypertens. 2003; 17(3): 207-212.
  31. Miranda R. D., Mion D. Jr., Rocha J. C. et al. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study. Clin. Ther. 2008; 30(9): 1618-1628.
  32. Yadhav U. Evaluation of efficacy and tolerabity of perindopril and amlodipine combination in the management of patients moderate-to-severy hypertension in India. In: Presentations on 23rd Annual. scientific meeting of the ASH. J. Clin. Hypertens. 2008.
  33. Symbio: Results of a longitudinal study of optimized blood pressure-lowering THERAPY with fixed combination perindopril/amlodipine. ESH 2010; Abstract.
  34. Girich M. P., Bahl V., Jadhav U. et al. Blood pressure control of fixed dose, perindopril/amlodipine combination treatment in hypertensive patients uncontrolled on monotherapy or on two combination therapy. In: ESH Congress 2010; Abstract.
  35. Bangalore S., Kamalakkannan G., Parkar S., Messerli F. H. Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med. 2007; 120(8): 713-719.
  36. Williams B., Lacy P. S., Thom S. M. et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the conduit artery function evaluation (CAFE) study. Circulation 2006; 113: 1213- 1225.
  37. Asmar R. G., London G. M., O'Rourke M. et al. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patients: a comparison with atenolol. Hypertension 2001; 38: 922-926.
  38. Bertrand M. E., Ferrari R., Remme W. J. et al. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am. Heart J. 2010; 159(5): 795-802.
  39. Ferrari R. Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine. Curr. Med. Res. Opin. 2008; 24(12): 3543-3557.
  40. Opie L. H., Schall R. Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy. J. Am. Coll. Cardiol. 2002; 39(2): 315-322.
  41. Ostergren J., Poulter N. R., Sever P. S. et al for the ASCOT investigators. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. J. Hypertens. 2008; 26: 2103-2111.
  42. Scheen A. J. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004; 64: 2537-2565.
  43. Hayashi K., Wakino S., Sugano N. et al. Ca2+ channel subtypes and pharmacology in the kidney. Circ. Res. 2007; 100(3): 342-353.
  44. Bakris G. L., Toto R. D., McCullough P. A. et al. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int. 2008; 73(11): 1303-1309.
  45. Reboldi G., Gentile G., Angeli F., Verdecchia P. Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vasc. Hlth Risk M anag. 2009; 5(1): 411-427.
  46. Epstein M. The benefits of ACE inhibitors and calcium antagonists in slowing progressive renal failure: focus on fixed-dose combination antihypertensive therapy. Ren. Fail. 1996; 18(6): 813-832.
  47. Lindgren P., Buxton M., Kahan T. et al. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. Heart 2008; 94(2): e4.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies